Survivorship Care Plan in Promoting Physical Activity in Breast or Colorectal Cancer Survivors in Wisconsin

Sponsor
University of Wisconsin, Madison (Other)
Overall Status
Completed
CT.gov ID
NCT02677389
Collaborator
(none)
100
1
2
18.8
5.3

Study Details

Study Description

Brief Summary

This randomized pilot clinical trial studies how well survivorship care plan works in promoting technology-based physical activity in breast or colorectal cancer survivors in Wisconsin. A survivorship care plan may help doctors to better understand how they can help people who have been diagnosed with cancer to become more physically active. It is not yet known whether a standardized cancer survivor plan used as part of routine care or a technology-based physical activity intervention is better in promoting physical activity in breast or colorectal cancer survivors.

Detailed Description

PRIMARY OBJECTIVES:
  1. Establish the feasibility of enrolling breast and colorectal cancer survivors along with a co-survivor into a randomized physical activity promotion trial.

  2. Determine the short-term effect of an enhanced survivorship care plan (SCP) compared to the standard SCP on objectively-measured physical activity among survivors and co-survivors.

OUTLINE: Participants are randomized to 1 of 2 arms.

ARM I (Enhanced SCP): Participants receive an enhanced SCP, comprised of a personalized document that summarizes treatment and follow up recommendations, including basic physical activity guidance. Participants also receive a copy of the United States Department of Agriculture (USDA) Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on "Healthy Habits" at 1, 2, 4, and 8 weeks. Specific topics in emails include "positive self-talk", "daily relaxation breathing techniques", "better sleep", and "ways to find pleasure". Participants also wear a Fitbit web-integrated physical activity tracker daily for 12 weeks and receive email feedback specific to each participant based on a series of factors, including their Fitbit data, Emails may provide encouragement, such as "keep up the good work", and/or very specific instructions regarding compliance with the intervention, goals for meeting physical activity goals, potential strategies to increase/maintain levels of physical activity, etc., and technical or how-to support including how to use the device and website, or questions about goal-setting.

ARM II (Control): Participants receive a standard SCP, comprised of a personalized document that summarizes treatment and follow up recommendations, including basic physical activity guidance. Participants also receive a copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on "Healthy Habits" at 1, 2, 4, and 8 weeks. Specific topics in emails include "positive self-talk", "daily relaxation breathing techniques", "better sleep", and "ways to find pleasure".

Study Design

Study Type:
Interventional
Actual Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Active Living After Cancer: Building a Physical Activity Intervention Into Clinical Care for Breast and Colorectal Cancer Survivors in Wisconsin
Actual Study Start Date :
Jul 1, 2016
Actual Primary Completion Date :
Jan 24, 2018
Actual Study Completion Date :
Jan 24, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: Arm I (Enhanced SCP)

See Detailed Description

Other: Educational Intervention
Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
Other Names:
  • Education for Intervention
  • Intervention, Educational
  • Other: Internet-Based Intervention
    Receive email and technical or how-to support from study coordinator

    Device: Monitoring Device
    Wear a Fitbit web-integrated physical activity tracker
    Other Names:
  • Monitor
  • Fitbit
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other Names:
  • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies

    Active Comparator: Arm II (SCP)

    Participants receive a standard SCP, comprised of a treatment and follow up recommendations, including basic physical activity guidance, copy of the USDA Dietary Guidelines for Americans, as well as standardized emails with wellness tips and information on stress management provided from the American Heart Association's website on "Healthy Habits" at 1, 2, 4, and 8 weeks. Specific topics in emails include "positive self-talk", "daily relaxation breathing techniques", "better sleep", and "ways to find pleasure".

    Other: Educational Intervention
    Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
    Other Names:
  • Education for Intervention
  • Intervention, Educational
  • Other: Quality-of-Life Assessment
    Ancillary studies
    Other Names:
  • Quality of Life Assessment
  • Other: Questionnaire Administration
    Ancillary studies

    Outcome Measures

    Primary Outcome Measures

    1. Feasibility as defined by recruitment rate [Up to 12 weeks]

      Measures include recruitment rate (ability to recruit ≥5 patients per month to the study), retention rate (ability to collect all measures on ≥80% of randomized patients) and patient satisfaction with SCP, Fitbit, and physical activity intervention materials, both overall and by cancer type (breast/colon).

    Secondary Outcome Measures

    1. Physical activity as measured by the ActiGraph GT3X+ accelerometer (Arm I) [Up to 12 weeks]

      ActiGraph accelerometer will be compared between the arms (intervention and control) using a mixed effects model for repeated daily measures at week 0 (baseline) and week 12. Explanatory factors will be study week, measurement day and the randomization group by week interaction (the primary parameter of interest).

    2. Physical activity as measured by the ActiGraph GT3X+ accelerometer (Arm II) [Up to 12 weeks]

      ActiGraph GT3X+ accelerometer will be compared between the arms (intervention and control) using a mixed effects model for repeated daily measures at week 0 (baseline) and week 12. Explanatory factors will be study week, measurement day and the randomization group by week interaction (the primary parameter of interest).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    30 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • CRITERIA FOR SURVIVORS:

    • Have a diagnosis of stage I-III female breast cancer or colorectal cancer within the past 5 years; bilateral or multiple primary breast cancers are permitted; individuals who have had more than one type of cancer (e.g., both breast and melanoma) are permitted as long as the breast (or colorectal) diagnosis meets the other criteria and primary treatment for any cancer is not ongoing

    • Have completed primary treatment for their cancer; primary treatment will be defined as having completed all (a) definitive cancer surgery, (b) (neo)adjuvant chemotherapy, and/or (c) (neo)adjuvant radiation; breast cancer patients still receiving adjuvant endocrine or human epidermal growth factor receptor 2 (HER2) targeted therapies are eligible, as would colon cancer patients receiving a targeted agent; if there is any question whether a patient meets this eligibility requirement, Dr. Tevaarwerk (co-I, Oncology) will adjudicate

    • Are willing to attempt increase in physical activity level

    • Have a co-survivor (friend or family member) willing to participate in this research study

    • ELIGIBILITY CRITERIA FOR BOTH SURVIVORS AND CO-SURVIVORS:

    • Have high-speed access to the internet at home or work; This could be broadband, digital subscriber line (DSL), and/or access on a smartphone or tablet via a wireless provider

    • Fluent in English

    • Willing and able to attend study visits at the University of Wisconsin (UW) - Madison

    • Co-survivors must be over the age of 18 years

    Exclusion Criteria:
    • EXCLUSION CRITERIA SPECIFIC TO SURVIVORS:

    • Survivors must not have evidence of recurrent or metastatic disease

    • Survivors must not have previously received an SCP or are unwilling to receive one

    • Survivors must not be performing >= 100 minute (min)/week of moderate-vigorous physical activity

    • EXCLUSION CRITERIA FOR BOTH SURVIVORS AND CO-SURVIVORS:

    • Conditions that would interfere with the safety of moderate-to-vigorous intensity physical activity; participants will be screened for safety using the validated Physical Activity Readiness Questionnaire (PAR-Q)

    • Any physical or mental health condition that would interfere with full participation in the study, including individuals who are unable to read consent materials or appear to lack the capacity to consent

    • Any individual considered to be that of a "vulnerable group", including pregnant women and prisoners

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Wisconsin Carbone Cancer Center Madison Wisconsin United States 53792

    Sponsors and Collaborators

    • University of Wisconsin, Madison

    Investigators

    • Principal Investigator: Lisa Cadmus-Bertram, University of Wisconsin, Madison

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    University of Wisconsin, Madison
    ClinicalTrials.gov Identifier:
    NCT02677389
    Other Study ID Numbers:
    • UW15059
    • NCI-2016-00111
    • 2015-1295
    • A176000
    • EDUC\KINESIOLOGY\KINESIO
    First Posted:
    Feb 9, 2016
    Last Update Posted:
    Nov 18, 2019
    Last Verified:
    Feb 1, 2019
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 18, 2019